Ronald Rains
Pulmonary Disease · Colorado Springs, CONPI 1023013745
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,024 of the $5,242 with a category attached, or 76.8%. AstraZeneca accounts for 84.9% of it on its own, with 19 other manufacturers making up the rest.
Across 73 payments — averaging $71.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$131
- Boehringer Ingelheim$90
- Harmony Biosciences LLC$68
- Grifols USA, LLC$63
- Actelion Pharmaceuticals US, Inc.$60
- plus $381 from 14 others
Across 16 payments — averaging $16,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$252K
- Ferring International Pharmascience Center US$6K
What the payments were for
- Consulting fees$4,02477%
- Food & beverage$1,21823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $4,450 |
| GSK | 11 | $131 |
| Boehringer Ingelheim | 5 | $90 |
| Harmony Biosciences LLC | 2 | $68 |
| Grifols USA, LLC | 3 | $63 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| AbbVie | 3 | $53 |
| Philips North America LLC | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| United Therapeutics Corporation | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Genentech USA, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| GE HealthCare | 1 | $18 |
| Merck | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$4,024
How this compares
$5,242 in reported general payments places this provider in the 70th percentile of 248 pulmonary disease providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Advair HfaFluticasone Propion/Salmeterol | 16 | $8,050 |
| Sildenafil Citrate | 11 | $973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $932 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Colorado Springs
- Christopher MerrickColorado Springs$34K
- Andrew BoulosColorado Springs$14K
- Lalith UragodaColorado Springs$12K
- Russell LeeColorado Springs$11K
- Dheeraj DhotreColorado Springs$9K
- Timothy RummelColorado Springs$8K
- Yogesh ShresthaColorado Springs$7K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.